Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons.
about
How addictive drugs disrupt presynaptic dopamine neurotransmissionMethamphetamine inhibits antigen processing, presentation, and phagocytosisVesicular monoamine transporter 2: role as a novel target for drug developmentRegulation of dopamine transporter activity by carboxypeptidase EDopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents.Rats that differentially respond to cocaine differ in their dopaminergic storage capacity of the nucleus accumbensDifferential effect of quinpirole and 7-OH-DPAT on the spontaneous [(3)H]-dopamine efflux from rat striatal synaptosomes.Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity.Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.Essential role of NMDA receptor channel ε4 subunit (GluN2D) in the effects of phencyclidine, but not methamphetamine.Ethanol alters endosomal recycling of human dopamine transporters.Regulation of quantal size by presynaptic mechanisms.Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review.Molecular mechanisms of amphetamine actions in Caenorhabditis elegansExtended findings of brain metabolite normalization in MA-dependent subjects across sustained abstinence: a proton MRS study.Comparison of (+)-methamphetamine, ±-methylenedioxymethamphetamine, (+)-amphetamine and ±-fenfluramine in rats on egocentric learning in the Cincinnati water maze.Amphetamine potency varies with dopamine uptake rate across striatal subregions.Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology.Attention deficit/hyperactivity disorder: pharmacotherapy.Speedball induced changes in electrically stimulated dopamine overflow in rat nucleus accumbens.Methamphetamine reduces human influenza A virus replication.An inverse correlation between the apparent rate of dopamine clearance and tonic autoinhibition in subdomains of the rat striatum: a possible role of transporter-mediated dopamine effluxRegulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.Differential electrophysiological changes in striatal output neurons in Huntington's disease.Changes in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure.Methamphetamine self-administration in mice decreases GIRK channel-mediated currents in midbrain dopamine neurons.A guide to neurotoxic animal models of Parkinson's diseaseAmphetamines, new psychoactive drugs and the monoamine transporter cycle.Action potentials and amphetamine release antipsychotic drug from dopamine neuron synaptic VMAT vesicles.In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusersMethamphetamine produces bidirectional, concentration-dependent effects on dopamine neuron excitability and dopamine-mediated synaptic currentsSingle cell measurement of dopamine release with simultaneous voltage-clamp and amperometry.Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synucleinInhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse.Age-related changes in orolingual motor function in F344 vs F344/BN rats.Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging studyIncreases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicityVitamin D3: A Role in Dopamine Circuit Regulation, Diet-Induced Obesity, and Drug ConsumptionAltered dopamine ontogeny in the developmentally vitamin D deficient rat and its relevance to schizophrenia
P2860
Q24631269-500D081C-4A1C-4FCB-858C-DB8260014D58Q24647304-F77F39E2-4FCE-400E-8403-D9E8ED7FA55BQ24647764-28739B9E-5FC5-4451-A0DF-C43D0903AD41Q28570586-C1F6B6EF-AE96-42D2-852C-02DC54510965Q30372768-30D8E479-0267-4D68-A9FA-682F19A415D0Q30481775-55DAF3AC-0DD7-44AC-845D-182AFBFA6360Q30493813-1C30F731-F369-4C97-AC91-121C0399352FQ31913355-E298416B-236A-4E89-8114-85D34A536E0BQ31992475-37977A6D-ED0F-4FE2-8B85-80B7E7529C9CQ33738102-645B1997-FDA4-4985-87CC-EB61FB9AE793Q33742221-C07E69BC-35CC-4F47-B4CB-EC6A47A7461BQ33795986-5C14C32D-6D4B-47E1-86DF-93F0E69B3187Q33863462-711A8AF9-D089-4B6A-9770-03CCCA764B21Q33867444-F21C03DF-DEF7-43A6-9300-E8627AF4613CQ34028189-7413236D-6036-47FA-9726-EA7549CDC449Q34133170-43315015-F78A-4985-8DCC-5721ED0A978CQ34367678-67585F87-951A-4E1D-90B6-6B1D5A47A00EQ34381228-D792363F-700A-4E70-8083-C20B0D6758C4Q34385110-7F04070C-8DA4-4709-9D2E-417EA5570EADQ34418634-D253BCEF-5AF9-4C95-B047-37EC7A919B84Q34459087-9575E441-2BCB-475B-A25A-EBE98FE57EB6Q34471943-D077B28F-5FCC-4F71-9F8E-3F08B55DDB31Q34663322-676E7BCE-7E8C-47F3-BBBF-4CA60EBFB4C1Q34673305-DBE7A434-1E77-4DEC-9A0A-147DFDB9D610Q34764514-F88EB617-CBD3-42D5-BE71-78751B356E67Q35172603-6699931A-0FE0-465F-AAAC-7B16CE59CE28Q35224281-4A7A85E0-38A3-4E9A-9E4A-4779A0F024A1Q35603488-6136D362-2C75-4D55-BAEA-419DACAEFDB5Q35853599-E062A84A-B543-4DAE-B9A7-CBAF3C9A99FBQ35961288-6D617FE2-7935-4867-80DD-87C1D9798B4BQ36118252-B3D97C2A-5C58-47FF-B018-9247401FD1F5Q36178903-68DD74AE-E595-444D-A2C2-E8B2B4C65294Q36486545-A44CC3D8-82E9-45B1-B168-B1FF29A37510Q36585297-1B41A13D-610F-44F4-BFFA-1D9BBFE821FEQ36593992-03A7D2FD-C9DA-43AE-B089-23F14B31DD88Q36596760-CF8E3024-418E-4B4C-BA36-7F9DECF7D6E3Q36623197-5E45577F-458D-4C2D-B284-80B27E189973Q36767159-92A8910F-F748-4F74-8006-ECC6D30D45A5Q36922890-16FA75E1-F5B3-4A22-B401-D5AD33520B1BQ37019129-59E68A23-1FB5-498F-B6E6-742CDCA00FB4
P2860
Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons.
description
1993 nî lūn-bûn
@nan
1993 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Amphetamine and other weak bas ...... e in ventral midbrain neurons.
@ast
Amphetamine and other weak bas ...... e in ventral midbrain neurons.
@en
Amphetamine and other weak bas ...... e in ventral midbrain neurons.
@nl
type
label
Amphetamine and other weak bas ...... e in ventral midbrain neurons.
@ast
Amphetamine and other weak bas ...... e in ventral midbrain neurons.
@en
Amphetamine and other weak bas ...... e in ventral midbrain neurons.
@nl
prefLabel
Amphetamine and other weak bas ...... e in ventral midbrain neurons.
@ast
Amphetamine and other weak bas ...... e in ventral midbrain neurons.
@en
Amphetamine and other weak bas ...... e in ventral midbrain neurons.
@nl
P2860
P1476
Amphetamine and other weak bas ...... ne in ventral midbrain neurons
@en
P2093
N T Maidment
P2860
P304
P356
10.1111/J.1471-4159.1993.TB03181.X
P407
P577
1993-02-01T00:00:00Z